Transcription News and Research

RSS

Elevated p21 expression may block key steps in viral life cycle

Elevated levels of p21, a protein best known as a cancer fighter, may be involved in the ability of a few individuals to control HIV infection with their immune system alone.

15 Mar 2011

New research: Fzd9 receptor can stimulate bone formation

New research shows that the Wnt receptor Frizzled-9 promotes bone formation, providing a potential new target for the treatment of osteoporosis. The study appears online on March 14 in The Journal of Cell Biology.

15 Mar 2011

Autoimmune response mediated by T lymphocytes may play vital role in pathogenesis of biliary atresia

Biliary atresia (BA) is an inflammatory obliterative cholangiopathy with unknown etiology, leading to progressive fibrosis and cirrhosis. Microarray technology, emerged as an indispensable research tool for gene expression profiling, has been used to study the mechanism underlying BA, and allows the simultaneous analysis of thousands of transcripts within a single experiment.

9 Mar 2011

New discovery in childhood respiratory disease

Researchers have identified a critical part of the process by which one of the world's most common and dangerous early childhood infections, respiratory syncytial virus, causes disease.

8 Mar 2011

Fumaric acid salts may protect against Multiple Sclerosis

Fumaric acid salts have been in use against severe psoriasis for a long time. About ten years ago, researchers in Bochum speculated that they may also have a favourable effect on Multiple Sclerosis as a result of their TH2 polarizing mechanisms.

8 Mar 2011

Two studies show how laminin plays a central role in breast cancer development

Laminin, long thought to be only a structural support protein in the microenvironment of breast and other epithelial tissues, is "famous" for its cross-like shape.

8 Mar 2011

Article outlines role of transcriptional mutagenesis in tumor development

DNA provides the instruction manual for all life forms. Occasionally, instructions are not carried out properly, and bad messages are sent leading to the creation of mutant proteins and possible tumor development.

5 Mar 2011

Scientist discovers new mechanism for regulation of gene expression

Dr. David Levin, Professor of Molecular & Cell Biology at Boston University Henry M. Goldman School of Dental Medicine and Professor of Microbiology at Boston University School of Medicine discovered recently a novel, evolutionarily conserved mechanism for the regulation of gene expression.

4 Mar 2011

New insight: p53 protein controls molecular crossroads in glucose metabolic pathway

The gene for the protein p53 is the most frequently mutated in human cancer. It encodes a tumor suppressor, and traditionally researchers have assumed that it acts primarily as a regulator of how genes are made into proteins.

3 Mar 2011

New findings disclose mechanisms that control Rb2/p130 gene expression in lung cancer cells

Despite innumerable studies on lung cancer, many aspects of the disease have yet to be understood, including the role played by the retinoblastoma-related protein Rb2/p130 in the evolution of the disease.

27 Feb 2011

New study discloses mechanism controlling Rb2/p130 gene expression in lung cancer cells

25 Feb 2011

Accelrys releases Pipeline Pilot NGS Collection at Molecular Medicine Tri-Conference

Accelrys, Inc. (NASDAQ:ACCL), the leading scientific informatics software and services company, today announced at the Molecular Medicine Tri-Conference its entrance in the rapidly growing next generation sequencing (NGS) market with the release of the NGS Collection for Pipeline Pilot.

24 Feb 2011

Orthopaedic groups select Entrada's automated clinical documentation solution

Two large orthopaedic groups have become the most recent customers of Entrada, a company changing the way physicians document patient encounters and use electronic health records (EHRs).

23 Feb 2011

Knocking out genes completely and exclusively in Natural Killer cells

Our immune systems contain three fundamentally different types of cell: B-cells, T-cells and the mysteriously named Natural Killer cells (NK cells), which are known to be involved in killing tumour cells and other infected cells. Experiments to investigate the function of NK cells have proven difficult to interpret because the interactions between the various components of the immune system make it almost impossible to isolate effects of individual cell types.

23 Feb 2011

Loss of 'twenty-four' gene makes it harder to wake up

Northwestern University scientists have discovered a new mechanism in the core gears of the circadian clock. They found the loss of a certain gene, dubbed "twenty-four," messes up the rhythm of the common fruit fly's sleep-wake cycle, making it harder for the flies to awaken.

17 Feb 2011

Study sheds light on novel functions of certain PCSK enzymes

Recent studies conducted at the Institut de recherches cliniques de Montr-al on a group of PCSK enzymes could have a positive impact on health, from cholesterol to osteoporosis.

17 Feb 2011

Study sheds new light on riboswitch that turns genes on or off in response to cell's energy needs

Scientists from The Scripps Research Institute have shed new light on a molecular switch that turns genes on or off in response to a cell's energy needs.

13 Feb 2011

Transcend fourth quarter revenue increases 26% to $26,976,000

TRANSCEND SERVICES, INC., a leading provider of clinical documentation solutions to the U.S. healthcare market, today announced its unaudited financial results for the fourth quarter and year ended December 31, 2010.

3 Feb 2011

Agilent introduces first commercial RNA target enrichment system

Agilent Technologies, Inc., today introduced SureSelect RNA Capture Kits, the first commercial RNA target enrichment system enabling geneticists to focus on specific genomic loci or transcripts of research interest. The RNA capture kits make it possible to precisely measure expression levels of genes of interest and detect allelic-specific expression, splicing events and gene fusions.

3 Feb 2011

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011